Clinical Trial Update: Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants [Phase 3]

View source ↗

Summary

GlaxoSmithKline completed a Phase 3 trial comparing immunogenicity and safety of two formulations of the DTPa-HBV-IPV/Hib vaccine in healthy infants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Hepatitis B
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• DTPa-HBV-IPV/Hib vaccine - Formulation A
• DTPa-HBV-IPV/Hib vaccine - Formulation B

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diphtheria, Hepatitis B | Phase 3 | Status: COMPLETED